CPHI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
China Pharma Holdings Inc (CPHI) is not a good buy for a beginner, long-term investor at this time. The company's financial performance is deteriorating significantly, with sharp declines in revenue, net income, EPS, and gross margin. Additionally, there are no positive trading signals, news catalysts, or strong technical indicators to support a buy decision. The lack of significant hedge fund or insider activity further suggests limited interest in the stock. Given the user's impatience and unwillingness to wait for optimal entry points, this stock does not align with their investment strategy.
The MACD is positive and expanding, indicating mild bullish momentum. RSI is neutral at 58.153, showing no clear overbought or oversold conditions. Moving averages are converging, which does not provide a strong directional signal. The stock is trading near its R1 resistance level of 0.631, with limited upside potential in the short term.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
The company's financial performance has deteriorated significantly in Q3 2025, with revenue, net income, EPS, and gross margin all showing sharp declines. No recent news or events to drive positive sentiment.
In Q3 2025, revenue dropped by 31.26% YoY to $756,217. Net income fell by 41.72% YoY to -$651,482. EPS declined by 73.85% YoY to -0.17, and gross margin dropped by 83.29% YoY to -7.89%. These metrics indicate severe financial underperformance.
No analyst ratings or price target changes available.
